Indivior Pharmaceuticals has delivered a strong 172.0% total return over the past 5 years, yet the stock now screens as undervalued on broader checks after a recent pullback. With a value score in the high range and the share price giving back some ground in recent weeks, investors are weighing whether the market is still underpricing the business.

• Indivior Pharmaceuticals is up 172.0% over 5 years, which signals that long term holders have already seen substantial gains even before considering the current valuation read.
• The planned all stock merger with Supernus Pharmaceuticals can support expectations for a larger central nervous system portfolio. At the same time, integration execution and achieving the targeted US$125 million in annual cost savings remain key risks to the combined equity story.
• The broader checks lean cheap, with the company scoring 6 out of 6 on value metrics that suggest the stock is pricing in cautious assumptions.

The issue now is whether Indivior Pharmaceuticals still offers an appealing entry point after a strong multi year run and the announced merger plan.

Scan beyond Indivior Pharmaceuticals and see how other potentially underpriced stocks with solid fundamentals are setting up for their next move in the 49 high quality undervalued stocks.

Is Indivior Pharmaceuticals a Bargain on Earnings?

The P/E ratio is a useful cross check for Indivior Pharmaceuticals because earnings sit at the center of how many investors frame drug company valuations. Indivior trades on a P/E of about 11.9x, which is well below the broader pharmaceuticals industry average of 16.9x and the peer group average of 23.2x. That already signals the market is pricing Indivior more cautiously than many other listed drug stocks.

The fair P/E ratio for Indivior, based on its specific profile, screens at about 17.7x. This is meaningfully higher than the current 11.9x level and indicates the shares are trading at a sizeable discount to what the model implies for a company with these characteristics. Despite the planned merger with Supernus, which would create a larger central nervous system portfolio, the current earnings multiple still points to a discounted valuation.

On the P/E multiple, Indivior Pharmaceuticals stock appears undervalued relative to both its tailored fair ratio and sector benchmarks.

The Indivior Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Indivior Pharmaceuticals pick up where the P/E and valuation checks leave off. They spell out the specific assumptions about Indivior Pharmaceuticals' future growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today's price, and they live on the company's Community page. Where a single ratio or model gives one figure, Narratives lay out the underlying future it relies on so you can monitor whether that path is playing out.

One of the top community narratives on Indivior Pharmaceuticals: 32% undervalued

"The Indivior Action Agenda includes Phase 1, which is focused on simplifying the business, and Phase II, Accelerate, which is set to start in 2026…"

Do you think there's more to the story for Indivior Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Indivior Pharmaceuticals screens as undervalued on earnings based on its current P/E relative to both peers and its tailored fair multiple. The broad valuation checks point in the same direction, although they do not answer how long it might take for any discount to close.

For you as an investor, the central question is whether the combined Indivior and Supernus business can deliver on integration, achieve the planned cost savings, and sustain the earnings profile that today’s multiple seems to discount. That discussion will likely determine whether the current valuation reflects opportunity or a fair price for the execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.